A5002791060- Transplantation: Methods and Outcomes
- Renal Transplantation Outcomes and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Organ Transplantation Techniques and Outcomes
- Pneumocystis jirovecii pneumonia detection and treatment
- Bone health and treatments
- Antifungal resistance and susceptibility
- Bone and Joint Diseases
- Tracheal and airway disorders
- Medical Imaging and Pathology Studies
- Pancreatic function and diabetes
- HIV/AIDS drug development and treatment
- Diabetes Treatment and Management
- Fungal Infections and Studies
University of California, San Francisco
2017-2024
University of California System
2017
Limited data and guidelines exist for using nirmatrelvir/ritonavir in solid organ transplant recipients stabilized on tacrolimus the treatment of mild-to-moderate coronavirus disease. Concern exists regarding impact utilizing a 5-d course with calcineurin inhibitors because significant drug-drug interactions between ritonavir, potent cytochrome P450 3A inhibitor, other substrates, such as tacrolimus.We report successful use 12 outpatient lung confirmed severe acute respiratory syndrome 2...
Most lung transplantation immunosuppression regimens include tacrolimus. Single nucleotide polymorphisms (SNPs) in genes important to tacrolimus bioavailability and clearance (ABCB1, CYP3A4, CYP3A5) are associated with differences pharmacokinetics. We hypothesized that these would impact immunosuppression-related outcomes. categorized ABCB1, CYP3A5 SNPs for 321 allograft recipients. Genotype effects on time therapeutic level, interactions antifungal medications, concentration dose (C0 /D),...
Invasive fungal infections can cause serious complications after lung transplant; therefore, prophylaxis with posaconazole is common. The delayed-release (DR) tablet preferred. Although the package insert states DR tablets cannot be crushed, recent data suggest it reasonable. We hypothesized that crushed could reach therapeutic levels in transplant recipients.